Aptuit, LLC has announced that it has acquired Kuecept Ltd to meet strong customer demand for specialist drug pre-formulation, formulation prototyping and formulation development services.
Located in London, Kuecept offers technical expertise in CRO services supporting preclinical drug development, in addition to providing pre-formulation testing, preclinical dose-vehicle screening and formulation development.
Aptuit CEO, Dr Jonathan Goldman, stated, ‘We offer solutions in the fields of integrated drug discovery, CMC and preclinical biosciences. The acquisition of Kuecept enhances our scientific expertise and capabilities in the pre-formulation development space. The addition allows us to improve the transition of compounds from medicinal chemistry in discovery through to formal regulatory-based drug product development.’
He added, ‘Kuecept scientists are skilled in utilising small milligram quantities of API in the critical de-risking phase of late stage discovery. Technologies such as hot melt extrusion, spray drying, wet and dry micronisation and cutting-edge microsphere chemistry are all routinely performed on very small amounts of API to develop robust and practical formulations.
‘Kuecept’s knowledge also further enhances our unique fully-integrated candidate to IND/CTA solution (INDiGO). We expect our customers to benefit from improved solubility solutions, reduced drug attrition and associated reductions in time and development costs.’
